Evidence map›Paper›PMID 31879534›Full record

ArticleWorld journal of gastrointestinal surgery2019

Polymyxin B hemoperfusion as a feasible therapy after source control in abdominal septic shock.

Jin Joo Kim, Young Jun Park, Ki Yoon Moon, Jin Hyeong Park, Yong Ki Jeong, Eun Young Kim

Registry-linked trialOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastrointestinal surgery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07788144 (Establishing Evidence Based Application of AN69-oXiris and PMX-HP Therapies Based on the Endotoxin Activity Assay in Septic Patients), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07788144 naenrolling by invitationnot on this mapstarted 2026, after this paper: background citation

Establishing Evidence Based Application of AN69-oXiris and PMX-HP Therapies Based on the Endotoxin Activity Assay in Septic Patients

TypeinterventionalSponsorKyoung Moo ImRan2026 to 2028Enrolled50ConditionsHemoperfusion, Sepsis, ICU, Endotoxin LevelsArmsAdsorptive Hemofilter for Continuous Renal Replacement Therapy, Polymyxin B-Immobilized Hemoperfusion Cartridge
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. [Extracorporeal procedures in sepsis].Die Anaesthesiologie · 2024
    Review
  2. Efficacy of Polymyxin B Hemoperfusion for Treatment of Sepsis.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2024
    Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Jin Joo KimDivision of Trauma and Surgical Critical Care, Department of Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 137-701, South Korea.
Young Jun ParkDepartment of Surgery, Seoul St. Mary's Hospital, Seoul 137-701, South Korea.
Ki Yoon MoonDepartment of Surgery, Seoul St. Mary's Hospital, Seoul 137-701, South Korea.
Jin Hyeong ParkDepartment of Surgery, Seoul St. Mary's Hospital, Seoul 137-701, South Korea.
Yong Ki JeongDepartment of Surgery, Seoul St. Mary's Hospital, Seoul 137-701, South Korea.
Eun Young KimDivision of Trauma and Surgical Critical Care, Department of Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 137-701, South Korea. freesshs@naver.com.
Seoul St. Mary's Hospital · KRCatholic University of Korea · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPolymyxin B hemoperfusion (PMX-HP) has been used as a treatment for intra-abdominal septic shock by absorbing and removing endotoxins of gram-negative bacilli.

aimTo investigate the clinical efficacy of PMX-HP in patients with gram-negative septic shock who underwent abdominal surgery.

methodsFrom January 2012 to December 2018, patients who had septic shock secondary to peritonitis were enrolled. They were classified into PMX-HP treated and control groups based on postopreative intervention using PMX-HP. The clinical outcomes were compared using 1:1 propensity score matching methods to balance the overall distribution between the two groups.

resultsAfter propensity score matching, 40 patients were analyzed (20 patients in the PMX group and 20 patients in the control group). The scores of total Sequential Organ Failure Assessment (SOFA) score, renal SOFA and coagulation SOFA were significantly improved in the PMX group but not in the control group. (from 11.2 ± 5.8 to 4.7 ± 3.5 in PMX group

conclusionPMX-HP is a feasible adjunct treatment for peritonitis in ICU patients with peritonitis for improved organ impairment and to stabilize hemodynamics. It would be helpful to enhance clinical outcomes especially in patients with complete elimination of the source of gram-negative bacilli infection by surgical procedure accompanied with conventional treatment of sepsis.

Indexed as

Intraabdominal septic shockPanperitonitisPolymyxin B hemoperfusionSepsisToraymyxin

Identifiers

PMID31879534
PMCPMC6912072
OpenAlexW2994644552

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.